The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia

Pain

Volumn 64, Issue 3, 1996, Pages 535-543

  Benedetti, Fabrizio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Cholecystokinin; Naloxone; Opiate; Pain; Placebo analgesia; Proglumide

Indexed keywords

CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; NALOXONE; OPIATE ANTAGONIST; OPIATE PEPTIDE; PLACEBO; PROGLUMIDE;

ADULT; ANALGESIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0029942941     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/0304-3959(95)00179-4     Document Type: Article

References (40)

1. Baber, N.S., Dourish, C.T. and Hill, D.R., The role of CCK, caerulein, and CCK antagonists in nociception, Pain, 39 (1989) 307-328.
2. Beinfeld, M.C., Cholecystokinin in the central nervous system: a minireview, Neuropeptides, 3 (1983) 411-427.
3. Chiodo, L.A. and Bunney, B.S., Proglumide: selective antagonism of excitatory effects of cholecystokinin in central nervous system, Science, 219 (1983) 1449-1451.
4. El-Sobsky, A., Dostrovsky, J.O. and Wall, P.D., Lack of effect of naloxone on pain perception in humans, Nature, 263 (1976) 783-784.
5. Paris, P.L., Komisaruk, B.R., Watkins, L.R. and Mayer, D.J., Evidence for neuropeptide cholecystokinin as an antagonist of opiate analgesia, Science, 219 (1983) 310-312.
6. Fields, H.L. and Levine, J.D., Placebo analgesia - a role for endorphins?, Trends Neurosci., 7 (1984) 271-273.
7. Gall, C., Lauterborn, J., Burks, D. and Seroogy, K., Colocalization of enkephalin and cholecystokinin in discrete areas of rat brain, Brain Res., 403 (1987) 403-408.
8. Gibbins, I.L., Furness, J.B. and Costa, M., Pathway-specific patterns of coexistence of substance P, calcitonin gene-related peptide, cholecystokinin and dynorphin in neurons of the dorsal root ganglia of the guinea pig, Cell Tissue Res., 248 (1987) 417-437.
9. Gracely, R.H., Dubner, R., Wolskee, P.J. and Deeter, W.R., Placebo and naloxone can alter postsurgical pain by separate mechanisms, Nature, 306 (1983) 264-265.
10. Grevert, P. and Goldstein, A., Effects of naloxone on experimentally induced ischemic pain and on mood in human subjects, Proc. Natl. Acad. Sci. USA, 74 (1977) 1291-1294.
11. Grevert, P. and Goldstein, A., Endorphins: naloxone fails to alter experimental pain or mood in humans, Science, 199 (1978) 1093-1095.
12. Grevert, P. and Goldstein, A., Placebo analgesia, naloxone, and the role of endogenous opioids. In: L. White, B. Tursky and G.E. Schwartz (Eds.), Placebo: Theory, Research, and Mechanisms, Guilford, New York, London, 1985, pp. 332-350.
13. Grevert, P., Albert, L.H. and Goldstein, A., Partial antagonism of placebo analgesia by naloxone, Pain, 16 (1983) 129-143.
14. Han, J.S., Ding, X.Z. and Fan, S.G., Cholecystokinin octapeptide (CCK-8): antagonism to electroacupuncture analgesia and a possible role in electroacupuncture tolerance, Pain, 27 (1986) 101-115.
15. Holaday, J.W., Long, J.B. and Tortella, F.C., Opioids and stress: effects upon nociception, behavior, and autonomic function following electroconvulsive shock, circulatory shock, or central nervous system injury. In: Y. Taché, J.E. Morley and M.R. Brown (Eds.), Neuropeptides and Stress, Springer, Berlin, 1989, pp. 256-275.
16. Itoh, S., Katsuura, G. and Maeda, Y., Caerulein and cholecystokinin suppress beta-endorphin-induced analgesia in the rat, Eur. J. Pharmacol., 80 (1982) 421-425.
17. Katsuura, G. and Itoh, S., Potentiation of beta-endorphin effects by proglumide in rats, Eur. J. Pharmacol., 107 (1985) 363-366.
18. Kellstein, D.E. and Mayer, D.J., Chronic administration of cholecystokinin antagonists reverses the enhancement of spinal morphine analgesia induced by acute pretreatment, Brain Res., 516 (1990) 263-270.
19. Lasagna, L., Drug interaction in the field of analgesic drugs, Proc. R. Soc. Med., 58 (1965) 978-983.
20. Lavigne, G.J., Hargreaves, K.M., Schmidt, E.A. and Dionne, R.A., Proglumide potentiates morphine analgesia for acute postsurgical pain, Clin. Pharmacol. Ther., 45 (1989) 666-673.
21. Lehmann, K.A., Schlusener, M. and Arabatsis, P., Failure of proglumide, a cholecystokinin antagonist, to potentiate clinical morphine analgesia. A randomized double-blind postoperative study using patient-controlled analgesia (PCA), Anesth. Analg., 68 (1989) 51-56.
22. Levine, J.D. and Gordon, N.C., Influence of the method of drug administration on analgesic response, Nature, 312 (1984) 755-756.
23. Levine, J.D., Gordon, N.C. and Fields, H.L., The mechanism of placebo analgesia, Lancet, 2 (1978) 654-657.
24. Lin, C.W. and Miller, T., Characterization of cholecystokinin receptor sites in guinea-pig cortical membranes using [(125)I] Bolton Hunter-cholecystokinin octapeptide, J. Pharmacol. Exp. Ther., 232 (1985) 775-780.
25. Lord, J.A.H., Waterfield, A.A., Hughes, J. and Kosterlitz, H.W., Endogenous opioid peptides: multiple agonists and receptors, Nature, 267 (1977) 495-499.
26. Paterson, S.J., Robson, L.E. and Kosterlitz, H.W., Classification of opioid receptors, Br. Med. Bull., 39 (1983) 31-36.
27. Price, D.D., Von der Gruen, A., Miller, J., Rafii, A. and Price, C., Potentiation of systemic morphine analgesia in humans by proglumide, a cholecystokinin antagonist, Anesth. Analg., 64 (1985) 801-806.
28. Rawlinson Crenshaw, M., Truth-telling and paternalism in the clinic: philosophical reflections on the use of placebos in medical practice. In: L. White, B. Tursky and G. Schwartz (Eds.), Placebo: Theory, Research and Mechanism, 1985.
29. Ross, S. and Buckalew, L.W., Placebo agentry: assessment of drug and placebo effects. In: L. White, B. Tursky and G.E. Schwartz (Eds.), Placebo: Theory, Research, and Mechanisms, Guilford, New York, 1985, pp. 67-82.
30. Smith, G.M., Egbert, L.D., Markowitz, R.A., Mosteller, F. and Beecher, H.K., An experimental pain method sensitive to morphine in man: the submaximum effort tourniquet technique, J. Pharmacol. Exp. Ther., 154 (1966) 324-332.
31. Smith, G.M., Lowenstein, E., Hubbard, J.H. and Beecher, H.K., Experimental pain produced by the submaximum effort tourniquet technique: further evidence of validity, J. Pharmacol. Exp. Ther., 163 (1972) 468-474.
32. Stengaard-Pedersen, K. and Larsson, L.I., Localization and opiate receptor binding of enkephalin, CCK and ACTH/beta-endorphin in the rat central nervous system, Peptides, 1 (1981) 3-19.
33. Suberg, S.N., Culhane, E.S., Carstens, E. and Watkins, L.R., Behavioral and electrophysiological investigations of opiate/cholecystokinin interactions. In: H.L. Fields, R. Dubner and F. Cervero (Eds.), Advances in Pain Research and Therapy, Vol. 9, Raven Press, New York, 1985, pp. 541-553.
34. Vanderhaegen, J.J., Signeau, J.C. and Gepts, W., New peptide in the vertebrate CNS reacting with antigastrin antibodies, Nature, 257 (1975) 604.
35. Watkins, L.R., Kinscheck, I.B., Kaufman, E.F.S., Miller, J., Frenk, H. and Mayer, D.J., Cholecystokinin antagonists selectively potentiate analgesia induced by endogenous opiates, Brain Res., 327 (1985a) 181-190.
36. Watkins, L.R., Kinscheck, I.B. and Mayer, D.J., Potentiation of morphine analgesia by the cholecystokinin antagonist proglumide, Brain Res., 327 (1985b) 169-180.
37. Wennogle, L.P., Steel, D.J. and Petrack, B. Characterization of central cholecystokinin receptors using a radioiodinated octapeptide probe, Life Sci., 36 (1985a) 1485-1492.
38. Wennogle, L.P., Steel, D.J. and Petrack, B. Characterization of cholecystokinin recognition sites in mouse cerebral cortex using a radioiodinated octapeptide probe, Ann. NY Acad. Sci. USA, 448 (1985b) 678-681.
39. Wilkins, W., Placebo controls and concepts in chemotherapy and psychotherapy research. In: L. White, B. Tursky and G.E. Schwartz (Eds.), Placebo: Theory, Research, and Mechanisms, Guilford, New York, 1985, pp. 83-109.
40. Winter, C.A. and Flataker, L., Studies of heptazone (6-morpholino-4,4-diphenyl-3-heptanone hydrochloride) in comparison with other analgesic drugs, J. Pharmacol. Exp. Ther., 98 (1949) 305-317.